A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety of Zytiga (Abiraterone Acetate Tablets 250 mg) in Indian Patients With Metastatic, Castration Resistant Prostate Cancer as Per Locally Approved Prescribing Information

Trial Profile

A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety of Zytiga (Abiraterone Acetate Tablets 250 mg) in Indian Patients With Metastatic, Castration Resistant Prostate Cancer as Per Locally Approved Prescribing Information

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Johnson & Johnson
  • Most Recent Events

    • 27 Jul 2017 Planned End Date changed from 30 Dec 2018 to 29 Aug 2019.
    • 24 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 17 Feb 2016 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top